Cingulate Inc. (NASDAQ: CING) reported a net loss of $5.9 million for the second quarter ended June 30, 2026, compared with a $5.0 million loss in the prior-year quarter. Cash and cash equivalents totaled $28.4 million at quarter-end.
The company said it is completing chemistry, manufacturing and controls work for a planned resubmission of the CTx-1301 ADHD treatment NDA following an FDA Complete Response Letter issued June 1, 2026.
- R&D expense was $1.5 million, down 44.9% from $2.7 million a year earlier.
- SG&A expense was $3.9 million, up 101.5% from $1.9 million in the prior-year quarter.
- First-half net loss was $15.2 million, compared with $8.8 million in the first half of 2025.
- Cingulate said its cash balance is expected to fund operations into mid-2027 under its current business plan.
- The company signed an exclusive services agreement with Prasco, LLC on July 21 to support commercial distribution infrastructure for CTx-1301.
$CINGW Hedge Fund Activity
We have seen 3 institutional investors add shares of $CINGW stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- HUDSON BAY CAPITAL MANAGEMENT LP removed 210,798 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $6,387
- CAPTRUST FINANCIAL ADVISORS added 15,200 shares (+inf%) to their portfolio in Q1 2026, for an estimated $460
- VIRTU FINANCIAL LLC added 12,626 shares (+inf%) to their portfolio in Q2 2026, for an estimated $241
- CITADEL ADVISORS LLC added 11,486 shares (+inf%) to their portfolio in Q1 2026, for an estimated $348
- UBS GROUP AG removed 913 shares (-61.2%) from their portfolio in Q1 2026, for an estimated $27
- GOALVEST ADVISORY LLC added 0 shares (+0.0%) to their portfolio in Q2 2026, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
